Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received Nasdaq notice for failing to maintain minimum $1.00 bid price for 30 consecutive business days.
Standard BioTools receives Nasdaq deficiency notice for failing $1 minimum bid price
Filed July 24, 2026 · Period ending July 22, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Standard BioTools on July 22 that its stock failed to maintain the required $1.00 minimum bid price for 30 consecutive business days, triggering a compliance review.
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule verify on EDGAR → -
high
The company has 180 days (until January 19, 2027) to regain compliance by closing above $1.00 for at least 10 consecutive business days; if unsuccessful, may transfer to Nasdaq Capital Market for an additional 180-day period.
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule verify on EDGAR → -
medium
Stock continues to trade normally on Nasdaq Global Select Market under ticker LAB during the compliance period with no impact on business operations or SEC reporting requirements.
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule verify on EDGAR → -
high
Management stated it intends to work toward compliance but acknowledged no assurance it can restore the minimum bid price or obtain extensions if needed.
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule verify on EDGAR →
Summary
Standard BioTools disclosed that Nasdaq notified the company on July 22, 2026 of a deficiency for failing to maintain the required $1.00 minimum bid price for 30 consecutive business days. This is a significant concern for shareholders as it raises the possibility of eventual delisting if the company cannot restore compliance. The company has until January 19, 2027 to close above $1.00 for at least 10 consecutive trading days, and if unsuccessful, may transfer to the Nasdaq Capital Market for an additional 180-day compliance period, potentially implementing a reverse stock split.
Management's acknowledgment that "there can be no assurance" of regaining compliance underscores the uncertainty facing the stock. While trading continues normally under ticker LAB during the compliance period, the deficiency notice signals sustained weakness in the stock price and raises questions about investor confidence in the company's business prospects. Shareholders should monitor whether the company can organically restore its stock price above $1.00 or whether it will need to pursue a reverse split, which would dilute existing shareholders' voting power and ownership percentage.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company intends to work toward restoring compliance within the prescribed timeframe. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable.
Management acknowledges uncertainty about whether the company can successfully restore compliance with the minimum bid price requirement within the allowed timeframe or obtain additional extensions if needed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 27, 2026 · How we verify